A chimeric antigen receptor (CAR) T-cell therapy that targets the protein mesothelin showed no evidence of major toxicity and had antitumor activity in patients with malignant pleural disease from mesothelioma, according to results from a phase I clinical trial presented at the AACR Annual Meeting 2019, March 29-April 3.
from EurekAlert! - Breaking News https://ift.tt/2Uo6Mnr
via IFTTT
Monday, April 1, 2019
Mesothelin-targeted CAR T-cell therapy shows early promise in patients with solid tumors
About Admin -
Author Description here.. Nulla sagittis convallis. Curabitur consequat. Quisque metus enim, venenatis fermentum, mollis in, porta et, nibh. Duis vulputate elit in elit. Mauris dictum libero id justo.